Pseudoephedrine News and Research

RSS

SCOLR Pharma's total revenue dips 2% in 2009, but significant improvements in operating expenses

SCOLR Pharma, Inc. today reported financial results for the twelve months ended December 31, 2009. The Company will host a live conference call on March 31, 2010, at 11:30 a.m. (Eastern Standard Time).

25 Mar 2010

Impax Laboratories announces record net income of $0.61 per diluted share for fourth-quarter 2009

Impax Laboratories, Inc. today reported its strongest financial results in its history due to record sales from its Global products sales channel.

25 Feb 2010

Teva Pharmaceutical Industries announces fourth-quarter and full-year 2009 financial results

Teva Pharmaceutical Industries Ltd. today reported record results for the quarter and year ended December 31, 2009.

16 Feb 2010

Wyoming lawkmaker pushes for reform, Mississippi Governor bans certain over-the-counter drugs

Associated Press/CNBC: "A veteran Wyoming state senator for the third time is pushing a bill he says would offer health insurance to people who couldn't afford it on the open market and also serve as an example to the rest of the nation of how to tackle rising health care costs. Sen. Charles Scott, R-Casper, has proposed a pilot program that calls for allowing 500 participants to enroll in Medicaid beginning in July. It would be limited to people whose family income is below 250 percent of the federal poverty level — $55,125 for a family of four.

15 Feb 2010

Combination of Motrin and Robitussin drugs is safe for adults and children

A viral e-mail currently making the rounds between private accounts and public message boards warning of a danger posed by mixing over-the-counter medications Motrin and Robitussin is unfounded.

6 Feb 2010

Some states mull requiring prescription for meth ingredients

"State and local efforts to thwart methamphetamine production by further limiting consumer access to a popular decongestant are pitting law enforcement against pharmacists and patients," USA Today reports.

2 Feb 2010

Consumers oppose prescription mandate; prefer alternative method to fight meth

Mississippians are expressing outrage at lawmakers' rush to change over-the-counter cold and allergy medicines containing pseudoephedrine (PSE) to a prescription (Rx) drug.

31 Jan 2010

Multi-state electronic tracking program to prevent diversion of common medicines for methamphetamine production

The National Association of Drug Diversion Investigators (NADDI) today announced a new initiative in the war on methamphetamine. The National Precursor Log Exchange (NPLEx) is a multi-state electronic tracking program that enforces purchase limitations on over-the-counter (OTC) medicines containing pseudoephedrine in real-time at the point of sale.

21 Nov 2009

Online patient support program for ADHD patients taking Vyvanse Capsules CII medication

Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the re-launch of FOCUS (http://www.vyvanseFOCUS.com), a free, online patient support program for adults taking once-daily Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), and the only online, branded personalized patient support program providing tips and tools for adults diagnosed with ADHD taking a prescription medication.

11 Nov 2009

Gastroschisis may be associated with infections during pregnancy

Results of an investigation conducted by University of Nevada, Reno researchers, public health officials and area physicians published this week in the Archives of Pediatrics & Adolescent Medicine, indicate that Washoe County experienced a cluster of a particular birth defect, gastroschisis, during the period April 2007 - April 2008.

7 Nov 2009

Teva Pharmaceutical launches Fexofenadine HCl and Pseudoephedrine HCl tablets

Teva Pharmaceutical Industries Ltd. announced today the commercial launch of Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets, the same as the sanofi-aventis U.S. allergy treatment Allegra-D® 12 Hour (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) Extended-Release Tablets. Teva's product is an alternative to the brand product, which had annual sales of approximately $293 million in the United States for the twelve months that ended June 30, 2009, based on IMS sales data.

4 Nov 2009

Prasco Laboratories to provide distribution services for generic versions of Allegra-D and Drisdol

Prasco Laboratories announced today that it has entered into agreements with Winthrop U.S., a business of sanofi-aventis U.S., to provide sales support and distribution services to Winthrop U.S. for authorized generic versions of Allegra-D® 12 Hour (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) extended-release tablets and Drisdol® (ergocalciferol) capsules in the United States under the Winthrop label.

3 Nov 2009

Shire to present key data on ADHD treatments at national psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV- (guanfacine) Extended Release Tablets, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, and Daytrana- (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.

31 Oct 2009

Shire's ADHD treatment data to be presented at the Honolulu psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV(TM) (guanfacine) Extended Release Tablets, Vyvanse®( ) (lisdexamfetamine dimesylate) Capsules CII, and Daytrana®( ) (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.

30 Oct 2009

AMRI files two new patent infringement lawsuits

AMRI announced today that it has filed two new patent infringement lawsuits in U.S. District Court in New Jersey against Dr. Reddy’s Laboratories, Ltd., Dr. Reddy’s Laboratories, Inc. and Sandoz, Inc. (“the defendants”) for infringement of AMRI’s U.S. Patent Number 7,390,906. The recently issued patent relates to the manufacturing process for the active ingredient in sanofi-aventis’s Allegra and AllegraD drug products.

16 Sep 2009

FDA approves Meda's ASTEPRO Nasal Spray

Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.

2 Sep 2009

Schering-Plough launches CLARITIN 12-Hour for non-drowsy relief from allergy symptoms

Schering-Plough Corporation (NYSE: SGP) today announced the introduction of CLARITIN 12-Hour, the only 12-hour allergy medicine found in the allergy aisle. New CLARITIN 12-Hour lasts all day and provides effective, non-drowsy relief from the worst indoor and outdoor allergy symptoms. The product is available for adults and children ages six and up.

1 Sep 2009

Doping drug does little to improve cyclists' performance

Scientists in New Zealand say many top cyclists may be putting their health at risk for no competitive gain by taking the doping drug pseudoephedrine.

2 Jul 2009

FDA stops Neilgen Pharmaceuticals and Advent Pharmaceuticals from making unapproved drugs

The U.S. Food and Drug Administration today announced that it had obtained a permanent injunction barring Neilgen Pharmaceuticals Inc. of Westminster, Md., its parent company, Advent Pharmaceuticals, Inc. (Advent), of East Windsor, N.J., and two of their officers, Bharat Patel and Pragna Patel, from manufacturing and distributing any unapproved, adulterated or misbranded drugs.

12 Apr 2009

Shire withdraws European application for Daytrana (Methylphenidate Transdermal System)

Shire plc has announced that it has decided to withdraw the European Marketing Authorization Application (MAA) for Daytrana (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

16 Mar 2009